TABLE 7.
Clinical success rate at test of cure in patients with and without serologic evidence of atypical pathogens at screeninga
| Group | No. of successes/no. in group (% successes) in amoxicillin-clavulanate treatment group:
|
|
|---|---|---|
| 2,000/125 mg | 875/125 mg | |
| Clinical PP test of cure population | 247 | 226 |
| Group A (at least one typical pathogen) (groups B and C combined) | 63/70 (90.0) | 43/52 (82.7) |
| Group B (typical pathogen only) | 37/43 (86.0) | 31/35 (88.6) |
| Group C (typical and atypical pathogens) | 26/27 (96.3) | 12/17 (70.6) |
| Group D (atypical pathogen only) | 43/47 (91.5) | 56/63 (88.9) |
| Group E (at least one atypical pathogen) (groups C and D combined) | 69/74 (93.2) | 68/80 (85.0) |
| ITT population | 322 | 311 |
| Group A (at least one typical pathogen) (groups B and C combined) | 78/87 (89.7) | 53/73 (72.6) |
| Group B (typical pathogen only) | 50/58 (86.2) | 39/52 (75.0) |
| Group C (typical and atypical pathogens) | 28/29 (96.6) | 14/21 (66.7) |
| Group D (atypical pathogen only) | 54/61 (88.5) | 71/82 (86.6) |
| Group E (at least one atypical pathogen) (groups C and D combined) | 82/90 (91.1) | 85/103 (82.5) |
a
See Table 3, footnote a.